LPC invests in the public equity markets primarily investing in growth and value stocks of small-cap and mid-cap companies employing fundamental analysis and conducting in-house research to make its investments. LPC utilizes a long only investment strategy and looks for opportunities that may be currently out of favor with the investment community. The portfolio emphasizes life sciences, leveraging the Scientific Advisory Board and proprietary research. We also focus on diagnostics and platform technologies for improved drug discovery, development, and delivery as well as therapeutics for central and peripheral nervous system disorders, cardiovascular and metabolic disease and cancer.
Public investments - Sector Allocations (as of 10/1/2018)